WRF
EGRX

Waddell & Reed Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Waddell & Reed Financial’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-56,000
Closed -$2.17M – 630
2016
Q2 		$2.17M Buy
56,000
+11,900
+27% +$496K ﹤0.01% 558
2016
Q1 		$1.79M Hold
44,100
– – ﹤0.01% 578
2015
Q4 		$3.91M Buy
+44,100
New +$3.48M 0.01% 518

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Waddell & Reed Financial's EGRX Position: Q3 2016 in Review

Waddell & Reed Financial sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2016, closing a stake of 56,000 shares — an estimated $2.17M sold.

Waddell & Reed Financial first reported a position in EGRX in Q4 2015 and held it in 3 quarters. The position peaked at $3.91M in Q4 2015. 137 funds tracked by Wall St. Rank hold EGRX as of Q3 2016.

  • Waddell & Reed Financial reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Waddell & Reed Financial sold 56,000 Eagle Pharmaceuticals, Inc. shares in Q3 2016, an estimated $2.17M.
  • Waddell & Reed Financial first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 3 quarters.
  • Waddell & Reed Financial's Eagle Pharmaceuticals, Inc. position peaked at $3.91M in Q4 2015.
  • 137 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2016.

Based on Waddell & Reed Financial's 13F filing for Q3 2016, filed 14 Nov 2016.